ANDA 200480, held by Septodont. Dyclonine Hydrochloride.
As of Nov 16, 2026, ANDA 200480 (Dyclopro), held by Septodont, was first approved by FDA on Nov 20, 2018, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE: Dyclonine HCl Topical Solution, USP is indicated for anesthetizing accessible mucous membranes (e.g., the mouth, pharynx, larynx, trachea, esophagus, and urethra) prior to various endoscopic procedures. Dyclonine HCl Topical Solution, USP, 0.5% topical anesthetic may also be used to block the gag reflex, to relieve the pain of oral ulcers or stomatitis and to relieve pain associated with ano-genital lesions.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 20, 2018 | Original application | Approved | None posted |
| Dyclopro0.5% · solution;topical | Dyclonine Hydrochloride | Rx |
| Dyclopro1% · solution;topical | Dyclonine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters